GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00219154 | Liver | HCC | neural tube development | 82/7958 | 152/18723 | 2.83e-03 | 1.33e-02 | 82 |
GO:00551191 | Liver | HCC | relaxation of cardiac muscle | 13/7958 | 17/18723 | 4.77e-03 | 2.02e-02 | 13 |
GO:00018384 | Liver | HCC | embryonic epithelial tube formation | 66/7958 | 121/18723 | 4.94e-03 | 2.07e-02 | 66 |
GO:00860642 | Liver | HCC | cell communication by electrical coupling involved in cardiac conduction | 17/7958 | 25/18723 | 8.94e-03 | 3.45e-02 | 17 |
GO:00721754 | Liver | HCC | epithelial tube formation | 70/7958 | 132/18723 | 9.29e-03 | 3.57e-02 | 70 |
GO:190184411 | Liver | HCC | regulation of cell communication by electrical coupling involved in cardiac conduction | 9/7958 | 11/18723 | 9.51e-03 | 3.60e-02 | 9 |
GO:0010882 | Liver | HCC | regulation of cardiac muscle contraction by calcium ion signaling | 18/7958 | 27/18723 | 9.75e-03 | 3.66e-02 | 18 |
GO:000164911 | Liver | HCC | osteoblast differentiation | 115/7958 | 229/18723 | 1.08e-02 | 3.99e-02 | 115 |
GO:00351484 | Liver | HCC | tube formation | 77/7958 | 148/18723 | 1.20e-02 | 4.39e-02 | 77 |
GO:0010881 | Liver | HCC | regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion | 15/7958 | 22/18723 | 1.35e-02 | 4.80e-02 | 15 |
GO:005109820 | Oral cavity | OSCC | regulation of binding | 212/7305 | 363/18723 | 3.88e-14 | 2.15e-12 | 212 |
GO:004339318 | Oral cavity | OSCC | regulation of protein binding | 121/7305 | 196/18723 | 8.92e-11 | 2.73e-09 | 121 |
GO:005109920 | Oral cavity | OSCC | positive regulation of binding | 105/7305 | 173/18723 | 5.88e-09 | 1.26e-07 | 105 |
GO:001605510 | Oral cavity | OSCC | Wnt signaling pathway | 227/7305 | 444/18723 | 1.10e-07 | 1.87e-06 | 227 |
GO:019873810 | Oral cavity | OSCC | cell-cell signaling by wnt | 227/7305 | 446/18723 | 1.75e-07 | 2.86e-06 | 227 |
GO:003209210 | Oral cavity | OSCC | positive regulation of protein binding | 54/7305 | 85/18723 | 4.05e-06 | 4.71e-05 | 54 |
GO:000150310 | Oral cavity | OSCC | ossification | 203/7305 | 408/18723 | 5.54e-06 | 6.19e-05 | 203 |
GO:003011110 | Oral cavity | OSCC | regulation of Wnt signaling pathway | 165/7305 | 328/18723 | 1.87e-05 | 1.80e-04 | 165 |
GO:000184110 | Oral cavity | OSCC | neural tube formation | 60/7305 | 102/18723 | 3.90e-05 | 3.43e-04 | 60 |
GO:000164910 | Oral cavity | OSCC | osteoblast differentiation | 118/7305 | 229/18723 | 7.51e-05 | 5.85e-04 | 118 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HRC | SNV | Missense_Mutation | novel | c.751G>A | p.Asp251Asn | p.D251N | P23327 | protein_coding | tolerated(0.12) | possibly_damaging(0.685) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
HRC | SNV | Missense_Mutation | novel | c.1345N>C | p.Glu449Gln | p.E449Q | P23327 | protein_coding | tolerated(0.3) | benign(0.067) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
HRC | SNV | Missense_Mutation | | c.1431N>C | p.Leu477Phe | p.L477F | P23327 | protein_coding | tolerated(0.12) | benign(0.044) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
HRC | SNV | Missense_Mutation | | c.1758N>G | p.Ile586Met | p.I586M | P23327 | protein_coding | deleterious(0) | possibly_damaging(0.854) | TCGA-AO-A1KR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
HRC | SNV | Missense_Mutation | novel | c.811N>T | p.His271Tyr | p.H271Y | P23327 | protein_coding | tolerated(0.06) | probably_damaging(0.982) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HRC | SNV | Missense_Mutation | rs766836022 | c.1951N>A | p.Glu651Lys | p.E651K | P23327 | protein_coding | deleterious(0) | possibly_damaging(0.885) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
HRC | SNV | Missense_Mutation | novel | c.1600G>A | p.Glu534Lys | p.E534K | P23327 | protein_coding | deleterious(0) | possibly_damaging(0.587) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
HRC | SNV | Missense_Mutation | | c.68N>A | p.Pro23His | p.P23H | P23327 | protein_coding | deleterious(0) | possibly_damaging(0.543) | TCGA-E2-A158-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | arimidex | SD |
HRC | SNV | Missense_Mutation | novel | c.704G>C | p.Gly235Ala | p.G235A | P23327 | protein_coding | tolerated(0.51) | benign(0) | TCGA-C5-A1M6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
HRC | SNV | Missense_Mutation | rs563550433 | c.872G>A | p.Arg291His | p.R291H | P23327 | protein_coding | tolerated(1) | benign(0) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |